We are studying the effects of siltuximab combined with corticosteroids for patients with severe acute graft versus host disease affecting the liver and gut. The goal is to see if this treatment is effective and safe for first-line therapy.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Graft Versus Host Disease (GVHD) is a serious condition that occurs when donor immune cells attack the recipient's body, particularly affecting the liver and gastrointestinal tract, leading to severe symptoms and complications.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.